Congruence Therapeutics
PrivateLast Round
Early Funding
Mar 19, 2026
Total Funding Raised
$136.5M
Momentum Score
25 /100
Company Overview
Congruence Therapeutics is a biotechnology company that develops pharmacological stabilizers for the treatment of rare diseases by leveraging computational and experimental drug discovery techniques to create validated small molecules targeting protein misfolding disorders.
Sector
Healthcare & Life Sciences
Verticals
Drug Discovery, Biotechnology, Medical AI, Precision Medicine
Business Model
B2B
Customer Profile
Revenue Share, Services & Consulting
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Congruence Therapeutics Comps
Public and private peers based on sector, stage, and business model.
Congruence Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Early Funding | Mar 19, 2026 | ||||
| Early Funding | Sep 4, 2025 | ||||
| Grant | Jul 24, 2025 | ||||
| Series A Extension | Mar 6, 2023 | ||||
| Series A | Feb 8, 2022 |
Key People
Founding team and executive leadership
Congruence Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Investissement Québec | Early Funding, Series A, Series A Extension |
| Amplitude Ventures | Early Funding, Series A Extension, Series A |
| Fonds de solidarité FTQ | Early Funding, Series A Extension, Series A |
| OrbiMed | Early Funding, Series A, Series A Extension |
| The Michael J. Fox Foundation for Parkinson's Research | Grant |
| Alexandria Venture Investments | Early Funding |
| Driehaus Capital Management | Early Funding, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 9, 2026
Attending the 25th Annual Needham Virtual Healthcare Conference.
- Apr 8, 2026
Launched Revenir™ for identifying novel binding sites.
Congruence Therapeutics Filings
SEC and related filings with document metadata.
| Typed | Date | Amount Offered | Amount Sold | Filling | Pages | Download |
|---|---|---|---|---|---|---|
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation | Sign Up to view | Mock Valuation |
Frequently Asked Questions
Common questions about Congruence Therapeutics's valuation, stock price, and market status.
